• LAST PRICE
    0.0193
  • TODAY'S CHANGE (%)
    Trending Up0.0006 (3.2086%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0176 / 0.0187
  • Day Range
    Low 0.0176
    High 0.0193
  • 52 Week Range
    Low 0.0016
    High 0.0600
  • Volume
    154,077
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 0.0187
TimeVolumeCUBT
01:15 ET10000.0176
01:26 ET50000.0187
01:35 ET313770.0187
01:37 ET25000.0193
01:39 ET100000.01875
01:42 ET100000.01875
02:08 ET340000.0187
02:09 ET25000.0193
03:07 ET350000.0193
03:32 ET200000.0187
03:50 ET2000.0182
03:54 ET25000.0193
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCUBT
Curative Biotechnology Inc
10.7M
-1.8x
---
United StatesNEXI
Neximmune Inc
10.8M
-0.2x
---
United StatesCNTX
Context Therapeutics Inc
10.5M
-0.7x
---
United StatesNDRA
ENDRA Life Sciences Inc
10.5M
-0.7x
---
United StatesGLMD
Galmed Pharmaceuticals Ltd
10.8M
-0.5x
---
United StatesIPIX
Innovation Pharmaceuticals Inc
10.9M
-2.1x
---
As of 2023-03-22

Company Information

Curative Biotechnology, Inc. (Curative Biotech) is a development-stage biomedical company focused on treatments for rare diseases and conditions. The Company is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. The Company has programs in three therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The Company’s pipeline products include IMT504, CURB906 and Metformin Reformulation. IMT504 is an immune therapy to treat rabies and an adjuvant for vaccines. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation is focused in treatment of intermediate and late-stage age-related macular degeneration (AMD) disease.

Contact Information

Headquarters
1825 Nw Corporate Blvd, Suite 110BOCA RATON, FL, United States 33431
Phone
---
Fax
---

Executives

Chairman of the Board, President
Paul Michaels
Chief Executive Officer, Chief Financial Officer, General Counsel
Richard Garr
Director
Michael Fish
Director, Chief Strategy Officer
Barry Ginsberg

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$10.7M
Revenue (TTM)
$0.00
Shares Outstanding
571.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.01
Book Value
$0.00
P/E Ratio
-1.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.